Mağara Aktinomisetleri: Antibiyotikler Altın Çağına Geri Mi Dönüyor?

Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Current Opinion in Microbiology, 2019;51: 72–80. doi:10.1016/j.mib.2019.10.008

Stephens LJ, Werrett MV, Sedgwick AC, et al. Antimicrobial innovation: a current update and perspective on the antibiotic drug development pipeline. Future Medicinal Chemistry, 2020;12(22): 2035–2065. doi:10.4155/fmc-2020-0225

Pancu DF, Scurtu A, Macasoi IG, et al. Antibiotics: conventional therapy and natural compounds with antibacterial activity-a pharmaco-toxicological screening. Antibiotics (Basel, Switzerland), 2021;10(4): 401. doi:10.3390/antibiotics10040401

Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection, 2012;18(3): 268–281. doi:10.1111/j.1469-0691.2011.03570.x

WHO. Antibiotic resistance 2020. (2.02.2023 tarihinde https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance adresinden ulaşılmıştır).

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet (London, England), 2022;399(10325): 629–655. doi:10.1016/S0140-6736(21)02724-0

Takahashi Y, Nakashima T. Actinomycetes, an inexhaustible source of naturally occurring antibiotics. Antibiotics (Basel, Switzerland), 2018;7(2): 45. doi:10.3390/antibiotics7020045

Donald L, Pipite A, Subramani R, et al. Streptomyces: still the biggest producer of new natural secondary metabolites, a current perspective. Microbiology Research, 2022;13(3): 418-465. doi:10.3390/microbiolres13030031

Prudence SMM, Addington E, Castaño-Espriu L, et al. Advances in actinomycete research: an actinobase review of 2019. Microbiology (Reading, England), 2020;166(8): 683–694. doi:10.1099/mic.0.000944

Li Q, Chen X, Jiang Y, et al. Morphological identification of actinobacteria. Dhanasekaran D, Jiang Y (eds.), Actinobacteria - Basics and Biotechnological Applications içinde. Rijeka, Hırvatistan: IntechOpen; 2016. doi:10.5772/61461

Sottorff I, Wiese J, Lipfert M, et al. Different secondary metabolite profiles of phylogenetically almost identical Streptomyces griseus strains originating from geographically remote locations. Microorganisms, 2019;7(6): 166. doi:10.3390/microorganisms7060166

Digital Atlas of Actinomycetes. Taxonomical. (2.02.2023 tarihinde https://atlas.actino.jp/ adresinden ulaşılmıştır).

Devanshi SR, Shah K, Arora S, et al. Actinomycetes as an environmental scrubber. Abdel-Raouf ME, El-Keshawy MH (eds.) Crude Oil - New Technologies and Recent Approaches içinde. Rijeka, Hırvatistan: IntechOpen; 2021. doi:10.5772/intechopen.99187

Farda B, Djebaili R, Vaccarelli I, et al. Actinomycetes from caves: an overview of their diversity, biotechnological properties, and insights for their use in soil environments. Microorganisms, 2022;10(2): 453. doi:10.3390/microorganisms10020453

Alam K, Mazumder A, Sikdar S, et al. Streptomyces: the biofactory of secondary metabolites. Frontiers in Microbiology, 2022;13: 968053. doi:10.3389/fmicb.2022.968053

Procópio RE, Silva IR, Martins MK, et al. Antibiotics produced by Streptomyces. The Brazilian Journal of Infectious Diseases, 2012;16(5): 466–471. doi:10.1016/j.bjid.2012.08.014

Rangseekaew P, Pathom-Aree W. Cave actinobacteria as producers of bioactive metabolites. Frontiers in Microbiology, 2019;10: 387. doi:10.3389/fmicb.2019.00387

Zada S, Sajjad W, Rafiq M, et al. Cave microbes as a potential source of drugs development in the modern era. Microbial Ecology, 2022;84(3): 676–687. doi:10.1007/s00248-021-01889-3

Herold K, Gollmick FA, Groth I, et al. Cervimycin A-D: a polyketide glycoside complex from a cave bacterium can defeat vancomycin resistance. Chemistry (Weinheim an der Bergstrasse, Germany), 2005;11(19): 5523–5530. doi:10.1002/chem.200500320

Stankovic N, Radulovic V, Petkovic M, et al. Streptomyces sp. JS520 produces exceptionally high quantities of undecylprodigiosin with antibacterial, antioxidative, and UV-protective properties. Applied Microbiology and Biotechnology, 2012;96(5): 1217–1231. doi:10.1007/s00253-012-4237-3

Jiang ZK, Guo L, Chen C, et al. Xiakemycin A, a novel pyranonaphthoquinone antibiotic, produced by the Streptomyces sp. CC8-201 from the soil of a karst cave. The Journal of Antibiotics, 2015;68(12): 771–774. doi:10.1038/ja.2015.70

Axenov-Gribanov DV, Voytsekhovskaya IV, Tokovenko BT, et al. Actinobacteria isolated from an underground lake and moonmilk speleothem from the biggest conglomeratic karstic cave in Siberia as cources of novel biologically active compounds. PloS One, 2016;11(2): e0149216. doi:10.1371/journal.pone.0149216

Gosse JT, Ghosh S, Sproule A, et al. Whole genome sequencing and metabolomic study of cave Streptomyces isolates ICC1 and ICC4. Frontiers in Microbiology, 2019;10: 1020. doi:10.3389/fmicb.2019.01020

Yücel S, Yamaç M. Selection of Streptomyces isolates from Turkish karstic caves against antibiotic resistant microorganisms. Pakistan Journal of Pharmaceutical Sciences, 2010;23(1): 1–6.

Rajput Y, Biswas J, Rai V. Potentiality test in antimicrobial activity and antibiotic sensitivity of subterranean Streptomyces strains isolated from Kotumsar cave of India. International Journal of Biological Chemistry, 2012;6(2): 53–60. doi:10.3923/ijbc.2012.53.60

Cheeptham N, Sadoway T, Rule D, et al. Cure from the cave: volcanic cave actinomycetes and their potential in drug discovery. International Journal of Speleology, 2013;42(1): 35–47. doi:10.5038/1827-806X.42.1.5

Maciejewska M, Adam D, Martinet L, et al. A phenotypic and genotypic analysis of the antimicrobial potential of cultivable Streptomyces isolated from cave moonmilk deposits. Frontiers in Microbiology, 2016;7: 1455. doi:10.3389/fmicb.2016.01455

Adam D, Maciejewska M, Naômé A, et al. Isolation, characterization, and antibacterial activity of hard-to-culture actinobacteria from cave moonmilk deposits. Antibiotics (Basel, Switzerland), 2018;7(2): 28. doi:10.3390/antibiotics7020028

Riquelme C, Enes Dapkevicius ML, Miller AZ, et al. Biotechnological potential of actinobacteria from canadian and azorean volcanic caves. Applied Microbiology and Biotechnology, 2017;101(2): 843–857. doi:10.1007/s00253-016-7932-7

Belyagoubi L, Belyagoubi-Benhammou N, Jurada V, et al. Antimicrobial activities of culturable microorganisms (actinomycetes and fungi) isolated from Chaabe cave, Algeria. International Journal of Speleology, 2018;47(2): 189–199. doi:10.5038/1827-806X.47.2.2148

Long Y, Jiang J, Hu X, et al. Actinobacterial community in Shuanghe cave using culture-dependent and -independent approaches. World Journal of Microbiology & Biotechnology, 2019;35(10): 153. doi:10.1007/s11274-019-2713-y

Hamedi J, Kafshnouchi M, Ranjbaran M. A study on actinobacterial diversity of Hampoeil cave and screening of their biological activities. Saudi Journal of Biological Sciences, 2019;26(7): 1587–1595. doi:10.1016/j.sjbs.2018.10.010

Çandiroğlu B, Doğruöz-Güngör N. The biotechnological potentials of bacteria isolated from Parsık Cave, Turkey. Johnson Matthey Technology Review, 2020;64(4): 396–406. doi:10.1595/205651320X15923194903811

Paun VI, Lavin P, Chifiriuc MC, et al. First report on antibiotic resistance and antimicrobial activity of bacterial isolates from 13,000-year old cave ice core. Scientific Reports, 2021;11(1): 514. doi:10.1038/s41598-020-79754-5